Fosun International (HKG:0656) said its indirect subsidiary Fosun Pharma Singapore sold 9.897 million shares in India's Gland Pharma (NSE:GLAND, BOM:543245) for about 28 billion rupees through block trades and open-market transactions.
The sale cuts Fosun International's stake in Gland Pharma to 45.76% from 51.76%, according to a Sunday Hong Kong bourse filing.
Gland Pharma will remain a subsidiary of Fosun Pharma (HKG:2196, SHA:600196), with its results continuing to be consolidated.
Shanghai Fosun Pharmaceutical plans to repurchase up to HK$1 billion of its H-shares, with the buyback mainly funded by proceeds from the sale of its Gland Pharma stake.
The shares were sold at an average price of about 2,828.78 rupees each, including transaction costs, a 2.72% discount to Gland Pharma's previous close.
Proceeds will be used mainly for research and development, share repurchases, and repayment of interest-bearing borrowings.